Insider Selling: SiBone (NASDAQ:SIBN) CEO Sells $220,017.47 in Stock

SiBone (NASDAQ:SIBN) CEO Laura Francis sold 14,957 shares of the stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $14.71, for a total value of $220,017.47. Following the completion of the transaction, the chief executive officer directly owned 503,444 shares in the company, valued at $7,405,661.24. The trade was a 2.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

SiBone Trading Down 0.9%

NASDAQ:SIBN opened at $14.68 on Friday. SiBone has a 1-year low of $11.48 and a 1-year high of $21.89. The business’s 50-day moving average price is $13.39 and its two-hundred day moving average price is $16.09. The company has a current ratio of 9.99, a quick ratio of 8.34 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $651.06 million, a price-to-earnings ratio of -37.64 and a beta of 0.67.

SiBone (NASDAQ:SIBN) last released its earnings results on Monday, May 11th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.07. SiBone had a negative return on equity of 9.56% and a negative net margin of 8.10%.The firm had revenue of $52.59 million for the quarter, compared to analyst estimates of $51.16 million. On average, equities analysts expect that SiBone will post -0.44 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have issued reports on SIBN. Wall Street Zen downgraded SiBone from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Truist Financial restated a “buy” rating and issued a $18.00 price target (down from $20.00) on shares of SiBone in a report on Tuesday, May 12th. Finally, TD Cowen lowered their price target on SiBone from $22.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, May 12th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, SiBone has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the company. ANTIPODES PARTNERS Ltd bought a new position in shares of SiBone during the fourth quarter worth about $29,000. Royal Bank of Canada grew its holdings in shares of SiBone by 98.5% during the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock worth $29,000 after buying an additional 736 shares in the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in shares of SiBone by 64,700.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock worth $38,000 after buying an additional 1,941 shares in the last quarter. State of Alaska Department of Revenue bought a new position in shares of SiBone during the third quarter worth about $39,000. Finally, Kemnay Advisory Services Inc. bought a new position in shares of SiBone during the fourth quarter worth about $53,000. 98.11% of the stock is currently owned by institutional investors.

About SiBone

Si-BONE, Inc is a commercial?stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA?cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.